Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

This systematic review reported positive outcomes with gender-affirming hormone therapy in Canada and emphasized the urgent need for standardized outcome measurement tools to enhance evidence-based practices.

In this study, serum PSA levels were higher in women with PCOS, suggesting it may serve as a marker for hyperandrogenism in this condition.

This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

This review re-evaluates the role of Serum Prostate Specific Antigen in prostate cancer diagnosis, suggesting it is most reliable for detecting cancer recurrences after treatment.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study found that estradiol and other sex steroids reduced the capture of monocytes by human endothelial cells in vitro, potentially inhibiting the formation of atherosclerosis by promoting nCAM polysialylation, which interferes with leukocyte tethering to the vascular endothelium.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study found that PSA concentrations in peripheral blood are related to androgen levels, suggesting that PSA is a valuable marker for diagnosing hyperandrogenism in women.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

In this study, five-year testosterone replacement therapy improved fasting blood sugar, HbA1c, and triglyceride levels in Japanese hypogonadal men without significantly affecting prostate-specific antigen levels.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.